Clinical trial · Interventional
Combination Chemoembolization and Radiofrequency Ablation for Hepatocellular Carcinoma Greater Than 3 cm
Phase 1 Study of Combination Chemoembolization and Radiofrequency Ablation for Hepatocellular Carcinoma Greater Than 3 cm
NCT00479050CI-TRIAL-00000737TACE-RFAcompletedPhase 1ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Combined the chemoembolization and Radiofrequency ablation for the hepatocellular carcinoma greater than 3 cm,the ablation volume of coagulation necrosis can be significantly increased,which may be enable effective treatment of patients with HCC greater than 3 cm.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Hepatocellular Carcinoma | Hepatocellular Carcinoma | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| chemoembolization ,Radiofrequency ablation | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- overall survival
- timeFrame
- 5 years
Secondary outcomes (1)
- measure
- tumor response
- timeFrame
- 1-6 months
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 45 Years
- Maximum age
- 75 Years
Show eligibility criteria text
Inclusion Criteria: Eligibility criteria were: 1. Not indicated for resection, 2. Liver function of Child-Pugh class A or B, 3. 3 or fewer lesion, each 3 cm greater and 7.5 cm less in greatest diameter, 4. No portal vein involvement or extrahepatic metastasis, 5. Lesions located at least 5mm away from the hepatic hilum or gall bladder and the common bile duct, 6. Platelet count≥6.0×103/mm3 and the prothrombin activity≥60%, and 7. No previous HCC treatment. Exclusion Criteria: Exclusion criteria were: 1. Encephalopathy, 2. Refractory ascites, 3. Active gastrointestinal bleeding, 4. Renal failure.
References
Publications (1)
- DERIVEDCheng BQ, Jia CQ, Liu CT, Fan W, Wang QL, Zhang ZL, Yi CH. Chemoembolization combined with radiofrequency ablation for patients with hepatocellular carcinoma larger than 3 cm: a randomized controlled trial. JAMA. 2008 Apr 9;299(14):1669-77. doi: 10.1001/jama.299.14.1669. PMID 18398079